Canine Heartworm Disease: Prevention and the Role of Combination Flea and Heartworm Pills

Introduction

Canine heartworm disease (HWD) is a life threatening parasitic infection caused by the filarial nematode Dirofilaria immitis [31]. The disease is transmitted through the bite of infected mosquitoes of the genera Aedes, Culex, and Anopheles [28, 31]. Adult worms reside in the pulmonary arteries and right ventricle, leading to progressive cardiopulmonary pathology [1, 2]. Over recent decades, the geographic range of D. immitis has expanded, driven by climate change, increased pet travel, and vector distribution shifts [3, 28, 32]. Prevention relies on monthly administration of macrocyclic lactones (MLs), often formulated in combination with ectoparasiticides to control fleas and ticks [4]. This article provides a detailed, evidence based review of HWD, with a focus on the role of combination flea and heartworm pills in prevention and control.

Etiology and Life Cycle

Dirofilaria immitis is a member of the family Onchocercidae, order Spirurida [28, 33]. Adult females measure 25–30 cm in length, while males are 12–20 cm [31]. The life cycle involves an obligate mosquito intermediate host. Microfilariae (first stage larvae, L1) circulate in the peripheral blood of an infected canine host and are ingested by a mosquito during a blood meal [31]. Within the mosquito, larvae develop through L2 and L3 stages; the extrinsic incubation period (EIP) is temperature dependent, requiring approximately 130–140 heartworm development units (HDUs) above a threshold of 14°C [34, 35]. Infective L3 larvae are deposited onto the skin during subsequent mosquito feeding and enter the host through the bite wound [31]. Larvae molt to L4 within 1–12 days, then to L5 (immature adults) by 50–70 days post infection [31]. Young adults migrate through the vasculature, reaching the pulmonary arteries approximately 70–90 days after infection [31]. Sexual maturation and reproduction begin around 6–7 months post infection, with microfilariae appearing in the blood 6–9 months after initial infection [31].

The bacterial endosymbiont Wolbachia pipientis plays a critical role in the biology and pathogenesis of D. immitis [5, 33]. Wolbachia are required for normal larval development, fertility, and survival of adult worms [5, 33]. The release of Wolbachia antigens during worm death triggers a robust inflammatory response in the host [5, 31].

Epidemiology and Risk Factors

Heartworm disease has a global distribution, with endemic foci on every continent except Antarctica [3, 28]. Prevalence varies widely by region. In the Caribbean, a study in Grenada reported a laboratory prevalence of 72 cases per 1000 dogs in 2003, declining to 15 per 1000 by 2015, with an epidemic peak between 2008 and 2010 [6]. Necropsy surveys of stray dogs in Grenada found 27.5% positive for D. immitis [7]. In Australia, a shelter based study in Queensland found 9.6% of dogs positive by combined antigen, modified Knott’s, and PCR testing, with significantly higher odds in northern Queensland (odds ratio 4.39) [8]. Autochthonous cases have been reported in previously non endemic areas, including Sydney, Australia (attributed to “baggage canine heartworm” via infected mosquitoes transported in luggage) [9], and Estonia, representing the northernmost autochthonous cases in the European Union [32]. In Ukraine, climate change and weak veterinary control have led to a rapid transition from sporadic to widespread disease [28]. In Brazil, a study in Porto Velho (Rondônia) found 12.8% seroprevalence in dogs, confirming local transmission [29].

Risk factors for HWD include age, sex, neuter status, and season. Adult and geriatric dogs have higher odds of infection compared to puppies (OR 3.9 and 2.1, respectively) [6]. Male dogs are at slightly higher risk (OR 1.3), while neutered dogs have lower odds (OR 0.4) compared to intact dogs [6]. Diagnosis is more likely during the dry season (OR 4.1) [6]. Lack of consistent preventive use is the predominant risk factor; poor owner compliance is frequently cited as the primary reason for infection [10, 11].

Pathogenesis and Clinical Signs

The primary pathology of HWD is proliferative pulmonary endarteritis caused by the mechanical and antigenic effects of adult worms residing in the pulmonary arteries [12, 13, 1]. The intimal layer of the arteries becomes thickened and roughened, leading to villous proliferation, thrombosis, and occlusion [12, 31]. These changes result in increased pulmonary vascular resistance and sustained precapillary pulmonary hypertension (PH) [12, 13]. PH is a common and serious complication, present in 47.4% of infected dogs in one echocardiographic study [13]. The right ventricle undergoes compensatory hypertrophy and may eventually fail, leading to right sided congestive heart failure and caval syndrome [14, 31].

Clinical signs are often insidious and correlate with worm burden and duration of infection. Early or low burden infections may be asymptomatic [15]. As disease progresses, dogs develop cough, exercise intolerance, dyspnea, and syncope [9, 31]. Caval syndrome, characterized by sudden onset of hemolysis, hemoglobinuria, and right heart failure, occurs when a large mass of worms obstructs the tricuspid valve and vena cava [14]. In a retrospective study from Grenada, caval syndrome was documented in a subset of infected dogs [14].

Cardiac biomarkers have been investigated for monitoring disease severity. Cardiac troponin I (cTnI) is elevated in both symptomatic and asymptomatic infected dogs, while N-terminal pro B type natriuretic peptide (NT-proBNP) is elevated only in dogs with clinical signs, suggesting cTnI may be more sensitive for early detection [16]. Tumor necrosis factor alpha (TNF-α) dynamics have also been studied in the context of diagnosis and treatment monitoring [17].

Diagnostic Approaches

Diagnosis of HWD relies on a combination of antigen testing, microfilarial detection, and imaging. The reference standard for antigen detection is a microwell based enzyme linked immunosorbent assay (ELISA) targeting adult female worm antigens [8]. Heat treatment of plasma prior to testing has been shown to increase optical density in positive samples, though it does not alter qualitative positivity [8]. Immunochromatographic rapid tests are also widely used in clinical practice [29].

Microfilarial detection is performed using the modified Knott’s test or direct smear [8, 29]. PCR can confirm D. immitis DNA and is particularly useful when antigen tests are positive but microfilariae are absent (occult infections) [8, 9]. In a study from Australia, all modified Knott’s positive samples were also PCR positive [8].

Thoracic radiography is a key tool for assessing cardiopulmonary changes. Subjective findings include increased sternal cardiac contact, reversed D heart shape, loss of pulmonary vessel margination, and enlargement of the right caudal lobar artery [18, 15]. Objective measurements such as modified vertebral heart size (VHS), manubrium heart score (MHS), and sternebral heart size (SHS) are feasible and correlate with disease severity [18]. The ratio of the right cranial lobar artery to the fourth thoracic vertebra (RCrLA/T4) is a useful vascular measurement [18]. In a Brazilian study, enlargement of caudal pulmonary arteries showed a strong positive correlation (0.732) with infection [15].

Echocardiography is essential for evaluating pulmonary hypertension and right ventricular function. The right pulmonary artery distensibility index (RPAD index) is a validated method for diagnosing PH (cutoff <29.5%) [12, 13]. The pulmonary vein to pulmonary artery ratio (PV:PA ratio) measured by M mode (cutoff ≤0.845) has high sensitivity (97%) and specificity (94%) for detecting moderate to severe PH [12]. Tissue Doppler imaging (TDI) parameters, including E’:A’ ratio, global TDI, and right myocardial performance index (R-TEI), provide additional diagnostic value [13].

Treatment Strategies

Adulticidal therapy is indicated for all dogs with confirmed HWD, unless contraindicated. The only approved adulticidal drug is melarsomine dihydrochloride, an arsenical compound administered via deep intramuscular injection into the paralumbar muscles [19, 5, 20]. Ultrasonography can be used to guide injection depth and minimize local complications [19]. The standard protocol involves two doses of melarsomine (2.5 mg/kg) given 24 hours apart, followed by a third dose one month later [20]. Strict exercise restriction is critical during and after treatment to reduce the risk of pulmonary thromboembolism [20].

In cases where melarsomine is declined or contraindicated, a “slow kill” approach using monthly macrocyclic lactone administration (e.g., ivermectin or moxidectin) combined with doxycycline (10 mg/kg twice daily for 28 days) is sometimes employed [5, 20, 10]. This combination targets Wolbachia, leading to worm sterility and gradual adult worm death [5]. However, the American Heartworm Society recommends against long term ML monotherapy due to concerns about resistance and prolonged antigenemia [20]. Despite this, a survey of veterinary practitioners in Mississippi found that 75% of heartworm positive dogs received slow kill therapy, primarily due to owner financial constraints [10]. Injectable moxidectin was the most common ML used in this context [10].

Doxycycline is the preferred tetracycline for anti-Wolbachia therapy, but minocycline may be considered as an alternative based on pharmacokinetic pharmacodynamic modeling, with a proposed dose of 3.75–5 mg/kg twice daily [21]. Minocycline has higher lipophilicity and lower protein binding than doxycycline, potentially offering better tissue penetration [21].

Prevention and the Role of Combination Flea and Heartworm Pills

Prevention of HWD relies on year round administration of macrocyclic lactones (ivermectin, milbemycin oxime, moxidectin, or selamectin) at monthly intervals [4, 3]. These drugs kill tissue stage larvae (L3 and L4) and prevent maturation to adults [22]. The concept of a “susceptibility gap” refers to the period when larvae are between L4 and early L5 and may be less susceptible to MLs; variation in drug timing may affect efficacy [22].

Combination products that pair an ML with an ectoparasiticide (e.g., afoxolaner, fluralaner, sarolaner, or spinosad) offer the advantage of simultaneous heartworm prevention and flea/tick control in a single oral dose [4]. These products are often referred to as dog heartworm and flea pill formulations. They improve owner compliance by reducing the number of monthly treatments required [10, 4]. The integrated approach addresses both endoparasite and ectoparasite burdens, which is particularly important in regions where fleas (Ctenocephalides felis) are vectors for other pathogens such as Dipylidium caninum and Bartonella spp. [4].

The efficacy of combination products is supported by pharmacokinetic and pharmacodynamic data demonstrating that the ML component achieves plasma concentrations sufficient to prevent larval development, while the ectoparasiticide component provides rapid kill of fleas and ticks [4]. No pharmacokinetic antagonism has been reported between MLs and isoxazoline or spinosyn class compounds [4].

A decision tree for prevention and treatment is presented in Figure 1.

flowchart TD
    A[Canine patient presented], > B{Annual heartworm test?}
    B, >|Negative| C[Start monthly combination flea/heartworm pill]
    B, >|Positive| D[Confirm with antigen + microfilarial test]
    D, > E{Clinical signs?}
    E, >|Yes| F[Echocardiography, radiography, biomarkers]
    E, >|No| G[Assess worm burden and PH risk]
    F, > H[Melarsomine protocol + doxycycline + exercise restriction]
    G, > H
    H, > I[Post-treatment antigen test at 6-12 months]
    I, >|Negative| C
    I, >|Positive| J[Consider retreatment or slow-kill]
    C, > K[Year-round compliance monitoring]

Table 1 summarizes the key diagnostic methods and their applications.

Conclusion

Canine heartworm disease remains a significant global health threat to dogs, with expanding geographic range and emerging resistance to macrocyclic lactones [10, 32, 34]. Accurate diagnosis requires a multimodal approach combining antigen testing, microfilarial detection, and advanced imaging. Treatment with melarsomine, doxycycline, and strict exercise restriction remains the gold standard, though slow kill protocols are frequently used due to financial constraints [20, 10]. Prevention through year round administration of combination flea and heartworm pills offers a practical solution to improve compliance and reduce the risk of infection. Veterinarians should tailor prevention recommendations based on local transmission risk, which can be assessed using temperature based models such as the HDU mapping tool [34, 35]. Continued surveillance and client education are essential to control this preventable disease.

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

References

[1] Sinanis T, Koutinas C, Diakou A, et al. Canine heartworm disease (dirofilariosis): pathogenesis and diagnosis of a multidimensional disease. Journal. 2017. URL: https://www.semanticscholar.org/paper/2be78af14e8bbc48f02eafa5082c58caaa6938d2

[2] Schwartz A. Canine heartworm disease: the current knowledge. Journal. 2016. URL: https://www.semanticscholar.org/paper/21e0ba8b136426397f1daf7ac03a3ff22e4c10e1

[3] Genchi C, Bowman D, Drake J. Canine heartworm disease (Dirofilaria immitis) in Western Europe: survey of veterinary awareness and perceptions. Parasit Vectors. 2014. URL: https://www.semanticscholar.org/paper/476da8ced75a94f6a3a0726956474c0d55dfa32a

[4] Sinanis T, Σινανης ΘΝ, Koutinas C, et al. Treatment and prevention of canine heartworm disease (dirofilariosis): what is new? Journal. 2017. URL: https://www.semanticscholar.org/paper/f9d7ed23b77cece6f8310d0c7b63608c01abe931

[5] Kramer L, Crosara S, Gnudi G, et al. Wolbachia, doxycycline and macrocyclic lactones: new prospects in the treatment of canine heartworm disease. Vet Parasitol. 2018. URL: https://www.semanticscholar.org/paper/0a0f050902d8bc4e39903f8ee566b06d6315bccb

[6] Kabuusu R, Stroup D, Pinckney R, et al. An analysis of time trends for canine heartworm disease in Grenada and its associated risk factors based on veterinary clinical pathology laboratory data base records between 2003 and 2015. Prev Vet Med. 2020. URL: https://www.semanticscholar.org/paper/80c24c85934a3d731c040bcd1cf613eb6eee0575

[7] Brown MC, Chikweto A, Tiwari K, et al. Prevalence of canine heartworm disease in stray dogs of Grenada, West Indies. Journal. 2017. URL: https://www.semanticscholar.org/paper/78bfd13bed5fb51bf59fb3ae1e97da4b49ee6bcc

[8] Panetta JL, Calvani N, Orr B, et al. Multiple diagnostic tests demonstrate an increased risk of canine heartworm disease in northern Queensland, Australia. Parasit Vectors. 2021. URL: https://www.semanticscholar.org/paper/509b357533d7d5d97835018414aede89dae98990

[9] McKeever B, Podadera J, Beijerink N, et al. Suspect ‘baggage canine heartworm’ case: canine heartworm disease in a dog from Sydney, New South Wales. Aust Vet J. 2021. URL: https://www.semanticscholar.org/paper/f928f07a716cddc692c2e03a9c7900c3234c9ef4

[10] Ku T. Investigating management choices for canine heartworm disease in northern Mississippi. Parasit Vectors. 2017. URL: https://www.semanticscholar.org/paper/36b50fb9651d5732e3e12d9faa1332025b2ef3d6

[11] Ku T. Investigating veterinary management choices for canine heartworm disease (Dirofilaria immitis) in northern Mississippi. Journal. 2017. URL: https://www.semanticscholar.org/paper/f37bc15409e77e8a530b0100d0e24ece98c3488e

[12] Matos J, Caro-Vadillo A, Falcón-Cordón Y, et al. Echocardiographic assessment of the pulmonary vein to pulmonary artery ratio in canine heartworm disease. Animals. 2023. URL: https://www.semanticscholar.org/paper/b7142b8b0c2cc2690bd2d075fe5b6134a1e7152d

[13] Matos J, García-Rodríguez SN, Costa-Rodríguez N, et al. Usefulness of tissue Doppler imaging for the evaluation of pulmonary hypertension in canine heartworm disease. Animals. 2023. URL: https://www.semanticscholar.org/paper/c751738eaf4839d131e3aadd15cf32cdcb584381

[14] Chikweto A, Bhaiyat MI, Lanza-Perea M, et al. Retrospective study of canine heartworm disease with caval syndrome in Grenada, West Indies. Vet Parasitol. 2014. URL: https://www.semanticscholar.org/paper/9d06b7908678528544e3a00f1bd3cb903e421680

[15] Lima NC, Paula MAS, Mattos RB, et al. Radiographic findings in dogs from an endemic area for heartworm disease in the state of Rio de Janeiro. Braz J Vet Med. 2025. URL: https://www.semanticscholar.org/paper/c32ff509ae1f262fa1c8a0b71b587e6d11983ac0

[16] Asawakarn S, Tachampa K, Taweethavonsawat P. Cardiac biomarkers for monitoring canine heartworm disease: a comparative study of N-terminal pro B type natriuretic peptide and cardiac troponin I levels. Wetchasan sattawaphaet (Thai J Vet Med). 2024. URL: https://www.semanticscholar.org/paper/aa11c6ac14ca0db27e2b8340b689372aa45062d1

[17] Spasojević Kosić L, Vračar V, Kozoderović G, et al. Detection and dynamics of tumor necrosis factor alpha in the diagnosis and treatment of canine heartworm disease. Veterinaria Italiana. 2024. URL: https://www.semanticscholar.org/paper/2a1addf72a8cca73641f819c152fbf88663a043c

[18] Kosić L. Feasibility and findings of different radiographic methods in diagnosing canine heartworm disease. Open Vet J. 2026. URL: https://www.semanticscholar.org/paper/b306c7a55860c411d653175893e9cfc5b013e70a

[19] Vörös K, Becker Z, Dudás Györki Z, et al. Ultrasonography of the paralumbar muscles as a new aid during melarsomine treatment in canine heartworm disease. Description and illustration of the method – A preliminary study. Acta Vet Hung. 2022. URL: https://www.semanticscholar.org/paper/8a9fd06e6f0a34fa082a305b0f40774070d209e5

[20] Dixon-Jimenez AC, Coleman A, Rapoport G, et al. Approaches to canine heartworm disease treatment among alumni of a single college of veterinary medicine. J Am Anim Hosp Assoc. 2018. URL: https://www.semanticscholar.org/paper/bbf340b1698b47617cd4a32454d1058be68e2b1b

[21] Papich M. Considerations for using minocycline vs doxycycline for treatment of canine heartworm disease. Parasit Vectors. 2017. URL: https://www.semanticscholar.org/paper/8ef0012a0c443c9eb25e93a29e40ed43f33e3521

[22] Chambers C. Variation of drug timing and its effect on “susceptibility gap” larvae in canine heartworm disease treatment. Journal. 2021. URL: https://www.semanticscholar.org/paper/ca35ca841db78a9c611a204ba10c2356db42f7d0

[23] Gabrielli S, Mendoza-Roldan J, Napoli E, et al. Human exposure to Dirofilaria immitis following a canine heartworm disease elimination program in Linosa Island (Sicily, Italy). Acta Tropica. 2025. URL: https://www.semanticscholar.org/paper/2fefc21e8996176a4af9e971902b00d7d0691ee2

[24] Monobe MM, Silva R, Melanchauski MS, et al. Canine heartworm disease in a Brazilian non-endemic area. Journal. 2016. URL: https://www.semanticscholar.org/paper/419abaf6bdaa212387c1fc0c0f8bd397795d67f6

[25] Tomohiro I, Jun S. Clinical experience of the treatment by oral administration of doxycycline and ivermectin combined with a single injection of melarsomine for canine heartworm disease. Journal. 2017. URL: https://www.semanticscholar.org/paper/5902c1d15a84c180fce6cc2cb5eee7cb45baf68a

[26] Savadelis MD. Focus on canine heartworm disease. Journal. 2017. URL: https://www.semanticscholar.org/paper/33545dc5c73d001ae75d223c191b52c5057745ae

[27] Montoya-Alonso JA, Balmori-de la Puente A, Costa-Rodríguez N, et al. A One Health perspective on heartworm disease: allergy risk in owners of infected dogs in Gran Canaria (Spain). Animals. 2025. URL: https://www.semanticscholar.org/paper/9b